Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;6(1):9-14.
doi: 10.4103/0974-1208.112370.

Prevalence of hepatic steatosis in women with polycystic ovary syndrome

Ritu Karoli  1 , Jalees Fatima, Ashok Chandra, Uma Gupta, Faraz-Ul Islam, Gagandeep Singh
Affiliations

Prevalence of hepatic steatosis in women with polycystic ovary syndrome

Ritu Karoli et al. J Hum Reprod Sci. 2013 Jan.

Abstract

Objective: Nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) both are known to be associated with insulin resistance and metabolic syndrome (MS). The aim of the study was to determine the presence of NAFLD and associated factors of hepatic steatosis in women with PCOS.

Materials and methods: A cross-sectional hospital based study of 54 women with PCOS and 55 healthy controls who were age and weight matched were included. Anthropometric parameters, biochemical and hormonal investigations were done in all the patients. Insulin resistance was calculated by Homeostasis model assessment (HOMA). Abdominal ultrasonography and biochemical tests were used to determine the presence of hepatic steatosis after excluding other causes liver disease.

Results: Women with PCOS had a higher prevalence of hepatic steatosis (67% vs 25%, P = 0.001) MS (35% vs. 7%, P < 0.01) and elevated transaminases (31% vs. 7%, P = 0.03) than controls. All patients with PCOS and controls with MS had presence of hepatic steatosis. Age, BMI, waist-hip ratio, HOMA-IR, HDL and PCOS diagnosis were the factors associated with presence of hepatic steatosis.

Conclusion: NAFLD is commonly present in women with PCOS in combination with other metabolic derangements. Evaluation for liver disease should be considered at an earlier age in women with PCOS, particularly those who have an evidence of MS.

Keywords: Insulin resistance; metabolic syndrome; non-alcoholic fatty liver disease; polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared

References

    1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–36. - PubMed
    1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–9. - PubMed
    1. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound Peripheral insulin resistance, Independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165–74. - PubMed
    1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;43:S99–112. - PubMed
    1. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289:3000–4. - PubMed

LinkOut - more resources